Loading…
Provides technology, data and commercial services to help life-sciences and pharma companies market and launch drugs.
Provides technology, data and commercial services to help life-sciences and pharma companies market and launch drugs.
Charges fees to drugmakers for work done by its own staff and platforms, from content creation and sales-and-marketing operations to regulatory documentation, usually under multi-year contracts. The US is its largest market. It listed on the Indian stock market in 2024.
In one line: A life-sciences-focused digital/commercial services firm.
Moat: narrow (process know-how, switching costs). Deep life-sciences domain expertise and embedded workflows create switching costs versus generic IT vendors.
Headquarters: Bengaluru, India · Founded: 1998 · Employees: 5,175
Size Indegene (INDGN.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.56B, the 457th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹609.75 on 6 Nov 2026.
Performance Over six months the shares gained 14.7%, against -4.0% for the median peer and 0.0% for the India market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 35.8% over the last twelve months (peer median +4.9%); the operating margin is 12.4% (peer median 9.1%).
Valuation It trades at 27.5× forward earnings against a peer median of 21.4× (6th most expensive of 13).
Price implies For today's price to make sense, revenue must grow about 30% a year for seven years (Req g). Recent delivered growth is +29%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.2 points above its cost of capital (15.8% WACC).
Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹41.3B | ₹35.1B | ₹28.4B | ₹25.9B | ₹23.1B |
| Revenue growth | — | +24% | +10% | +12% | — |
| Gross profit | ₹5.11B | ₹8.79B | ₹7.72B | ₹6.94B | ₹5.81B |
| EBITDA | ₹6.83B | ₹6.27B | ₹5.38B | ₹5.14B | ₹3.99B |
| Net income | ₹4.11B | ₹4.01B | ₹4.07B | ₹3.37B | ₹2.66B |
| Free cash flow | n/a | ₹6.19B | ₹4.61B | ₹4.92B | ₹1.00B |
| Capital expenditure | n/a | ₹443M | ₹300M | ₹107M | ₹188M |
| Total debt | ₹1.57B | ₹1.44B | ₹1.02B | ₹4.90B | ₹5.03B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Indegene INDGN.NS | $1.56B | +15% | +36% | 12% | 27.5× | 29.6% |
| Iqvia IQV | $44.8B | +52% | +9% | 14% | 19.7× | 17.3% |
| Accenture ACN | $154B | +44% | +6% | 15% | 17.8× | 3.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | INDGN.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.4% | +4.0% | 10th lowest of 21 |
| 6-month return | +14.7% | -4.0% | 7th highest of 21 |
| Distance from 52-week high | -4.4% | -19.8% | 3rd highest of 21 |
| Revenue growth (TTM) | +35.8% | +4.9% | 2nd highest of 19 |
| Operating margin | 12.4% | 9.1% | 8th highest of 19 |
| Forward P/E | 27.5× | 21.4× | 6th most expensive of 13 |
| Growth the price implies (Req g, 7 yrs) | 29.6% | -4.1% | 5th most demanding of 12 |
| Growth delivered (Del g) | +29.4% | +6.8% | 2nd highest of 12 |
| Hurdle (Req g minus delivered) | +0.2 pp | -4.3 pp | 5th most demanding of 12 |
| ROIC minus cost of capital | +1.2 pp | -0.1 pp | 9th highest of 19 |
| EV / EBITDA | 19.9× | 15.5× | 3rd most expensive of 7 |
| Net debt / EBITDA | -1.6× | 0.1× | 2nd least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Indegene INDGN.NS | India | $1.56B | +15% | +36% | 12% | 27.5× | 29.6% | +29.4% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.56B | -5% | +4% | 9% | 18.5× | -5.8% | +1.9% |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.55B | +53% | -6% | -19% | n/a | 49.9% | -13.2% |
| Nanobiotix NANO.PA | France | $1.54B | -42% | -77% | -392% | n/a | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.58B | +40% | +17% | 18% | 63.7× | 37.6% | +16.6% |
| Xiamen Kingdomway 002626.SZ | China | $1.58B | +15% | -3% | 11% | 30.0× | n/a | n/a |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.58B | -4% | +16% | 9% | 29.0× | n/a | n/a |
| LigaChem Biosciences 141080.KS | South Korea | $1.59B | -68% | -33% | -208% | n/a | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.53B | -17% | +2% | -2% | 42.9× | n/a | n/a |
| Ultragenyx Pharmaceutical RARE | United States | $1.52B | +22% | +16% | -64% | n/a | n/a | n/a |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.60B | -5% | +16% | 24% | n/a | -4.1% | +0.2% |
| Eton Pharmaceuticals ETON | United States | $1.61B | +236% | +81% | 16% | 27.9× | 39.6% | +359.6% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.62B | -4% | +7% | 17% | 16.2× | -4.5% | +6.8% |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.49B | -17% | +1% | 19% | 13.0× | -8.5% | +4.6% |
| ABL Bio 298380.KS | South Korea | $1.49B | -73% | -64% | -251% | n/a | n/a | n/a |
| Damora Therapeutics DMRA | United States | $1.46B | -2% | n/a | n/a | n/a | n/a | n/a |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +5% | +15% | 35% | 9.2× | -15.1% | +13.5% |
| Marksans Pharma MARKSANS.NS | India | $1.45B | +50% | +24% | 20% | 24.2× | 31.6% | +16.6% |
| Pacira Biosciences PCRX | United States | $1.45B | +57% | +6% | 4% | 11.8× | 14.9% | +11.1% |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.45B | -48% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.67B | -14% | -13% | 6% | 13.2× | -6.0% | -5.6% |